Display options
Cite
Suri SS, Fenniri H, Singh B. Nanotechnology-based drug delivery systems. J Occup Med Toxicol. 2007;2:16doi: 10.1186/1745-6673-2-16.
Suri, S. S., Fenniri, H., & Singh, B. (2007). Nanotechnology-based drug delivery systems. Journal of occupational medicine and toxicology (London, England), 216. https://doi.org/10.1186/1745-6673-2-16
Suri, Sarabjeet Singh, et al. "Nanotechnology-based drug delivery systems." Journal of occupational medicine and toxicology (London, England) vol. 2 (2007): 16. doi: https://doi.org/10.1186/1745-6673-2-16
Suri SS, Fenniri H, Singh B. Nanotechnology-based drug delivery systems. J Occup Med Toxicol. 2007 Dec 01;2:16. doi: 10.1186/1745-6673-2-16. PMID: 18053152; PMCID: PMC2222591.
Copy Download .nbib Format: NLM
Share it on

J Occup Med Toxicol. 2007 Dec 01;2:16. doi: 10.1186/1745-6673-2-16.

Nanotechnology-based drug delivery systems.

Journal of occupational medicine and toxicology (London, England)

Sarabjeet Singh Suri, Hicham Fenniri, Baljit Singh

Affiliations

  1. Department of Veterinary Biomedical Sciences and Immunology Research Group, University of Saskatchewan, 52 Campus Drive, Saskatoon, SK, S7N 5B4, Canada. [email protected].

PMID: 18053152 PMCID: PMC2222591 DOI: 10.1186/1745-6673-2-16

Abstract

Nanoparticles hold tremendous potential as an effective drug delivery system. In this review we discussed recent developments in nanotechnology for drug delivery. To overcome the problems of gene and drug delivery, nanotechnology has gained interest in recent years. Nanosystems with different compositions and biological properties have been extensively investigated for drug and gene delivery applications. To achieve efficient drug delivery it is important to understand the interactions of nanomaterials with the biological environment, targeting cell-surface receptors, drug release, multiple drug administration, stability of therapeutic agents and molecular mechanisms of cell signalling involved in pathobiology of the disease under consideration. Several anti-cancer drugs including paclitaxel, doxorubicin, 5-fluorouracil and dexamethasone have been successfully formulated using nanomaterials. Quantom dots, chitosan, Polylactic/glycolic acid (PLGA) and PLGA-based nanoparticles have also been used for in vitro RNAi delivery. Brain cancer is one of the most difficult malignancies to detect and treat mainly because of the difficulty in getting imaging and therapeutic agents past the blood-brain barrier and into the brain. Anti-cancer drugs such as loperamide and doxorubicin bound to nanomaterials have been shown to cross the intact blood-brain barrier and released at therapeutic concentrations in the brain. The use of nanomaterials including peptide-based nanotubes to target the vascular endothelial growth factor (VEGF) receptor and cell adhesion molecules like integrins, cadherins and selectins, is a new approach to control disease progression.

References

  1. CNS Drugs. 2004;18(14):981-8 - PubMed
  2. Peptides. 2003 Mar;24(3):487-501 - PubMed
  3. Nat Med. 2002 Sep;8(9):918-21 - PubMed
  4. J Control Release. 2005 Feb 16;102(3):657-68 - PubMed
  5. Biomaterials. 2007 Mar;28(8):1565-71 - PubMed
  6. Mol Ther. 2006 Oct;14(4):476-84 - PubMed
  7. EMBO J. 2003 May 15;22(10):2318-23 - PubMed
  8. J Control Release. 2004 Sep 30;99(2):259-69 - PubMed
  9. J Drug Target. 2002 Jun;10(4):317-25 - PubMed
  10. J Control Release. 2002 Oct 4;83(2):273-286 - PubMed
  11. Med Res Rev. 2002 Mar;22(2):146-67 - PubMed
  12. Injury. 2005 Nov;36 Suppl 4:S6-S13 - PubMed
  13. J Pharmacol Exp Ther. 2006 Dec;319(3):991-7 - PubMed
  14. Analyst. 2005 Apr;130(4):528-33 - PubMed
  15. J Am Chem Soc. 2001 Apr 25;123(16):3854-5 - PubMed
  16. J Control Release. 2005 Nov 2;108(1):84-96 - PubMed
  17. J Artif Organs. 2005;8(2):77-84 - PubMed
  18. Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1215-27 - PubMed
  19. J Control Release. 2000 Sep 3;68(3):419-31 - PubMed
  20. Proc Natl Acad Sci U S A. 2002 Apr 30;99 Suppl 2:6487-92 - PubMed
  21. J Cell Biol. 2000 Jul 24;150(2):F89-96 - PubMed
  22. J Pharmacol Exp Ther. 2006 Jun;317(3):1246-53 - PubMed
  23. Thromb Res. 2004;114(5-6):447-53 - PubMed
  24. Mol Pharm. 2004 Jan 12;1(1):77-84 - PubMed
  25. Biomed Microdevices. 2004 Mar;6(1):33-40 - PubMed
  26. Eur J Cancer. 2006 Jun;42(9):1309-15 - PubMed
  27. J Control Release. 2006 May 30;112(3):312-9 - PubMed
  28. Pharm Res. 1992 Jun;9(6):782-7 - PubMed
  29. Int J Pharm. 2003 May 12;257(1-2):111-24 - PubMed
  30. Curr Top Med Chem. 2004;4(14):1485-95 - PubMed
  31. J Med Chem. 2005 Feb 24;48(4):1098-106 - PubMed
  32. Thromb Haemost. 2005 Jan;93(1):106-14 - PubMed
  33. J Control Release. 2004 Mar 24;95(3):579-88 - PubMed
  34. Int J Cancer. 2004 May 1;109(5):759-67 - PubMed
  35. Eur J Pharmacol. 2006 Mar 8;533(1-3):341-50 - PubMed
  36. Science. 1998 Jan 16;279(5349):377-80 - PubMed
  37. J Antimicrob Chemother. 1996 Jan;37(1):105-15 - PubMed
  38. Adv Drug Deliv Rev. 2004 Sep 22;56(11):1649-59 - PubMed
  39. J Pharm Sci. 2006 Sep;95(9):1856-72 - PubMed
  40. Drug Dev Ind Pharm. 2007 May;33(5):569-75 - PubMed
  41. Int J Pharm. 2004 Oct 13;284(1-2):109-22 - PubMed
  42. Pigment Cell Res. 2005 Jun;18(3):150-9 - PubMed
  43. Nucleic Acids Res. 2005 Dec 13;33(22):e190 - PubMed
  44. Eur J Pharmacol. 2006 Mar 8;533(1-3):182-94 - PubMed
  45. J Drug Target. 2007 Apr;15(3):206-17 - PubMed
  46. J Control Release. 2003 Aug 28;91(1-2):115-22 - PubMed
  47. Biochem Soc Trans. 2005 Aug;33(Pt 4):684-8 - PubMed

Publication Types